Related Experiment Video
Updated: Jun 5, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs
Kevin Delgado-Calvo1, Elisa Lozano1, Oscar Briz1
1Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Institute of Biomedical Research of Salamanca (IBSAL), Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), University of Salamanca, Campus M. Unamuno s/n, 37007 Salamanca, Spain.
Abstract:
The pharmacological treatment of cholangiocarcinoma (CCA) is often hampered by tumor resistance. Improving our understanding of this issue is crucial for developing strategies that can overcome drug refractoriness. We have established and characterized two novel human cell sublines derived from extrahepatic CCA EGI-1 cells that are resistant to cisplatin and 5-fluorouracil (5-FU). Migration and proliferation were analyzed using holographic microscopy. The expression of genes involved in drug uptake and efflux was determined by RT-qPCR. Cross-resistance to commonly used antitumor drugs was assayed using the MTT test. EGI-1 sublines resistant to cisplatin (CR) or 5-FU (FR) exhibited more than a three-fold increase in resistance to cisplatin and 5-FU, respectively, and showed reduced proliferation, migration, and colony-formation rates, along with an altered cell cycle compared to wild-type cells, while retaining tumorigenic capacity. The analysis of the transportome showed downregulation of uptake transporters and upregulation of the export pumps MRP3/4. EGI-1 cells with acquired resistance to 5-FU demonstrated cross-resistance to irinotecan and gemcitabine, while cisplatin-resistant cells showed decreased sensitivity to 5-FU and platinum derivatives. These resistant cell lines offer valuable models for investigating the molecular basis of chemoresistance in CCA, providing a robust platform for the development and evaluation of novel therapeutic strategies.
Insights
Researchers developed novel cholangiocarcinoma (CCA) cell models resistant to chemotherapy drugs like cisplatin and 5-fluorouracil (5-FU). These models help study drug resistance and develop new treatment strategies for CCA.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cholangiocarcinoma (CCA) treatment is challenged by drug resistance.
- Understanding chemoresistance mechanisms is vital for effective CCA therapies.
Purpose of the Study:
- To establish and characterize novel human CCA cell sublines resistant to cisplatin and 5-fluorouracil (5-FU).
- To investigate the molecular basis of acquired chemoresistance in CCA.
Main Methods:
- Generation and characterization of cisplatin-resistant (CR) and 5-FU-resistant (FR) EGI-1 cell sublines.
- Analysis of cell proliferation, migration, and colony formation using holographic microscopy.
- Gene expression analysis of drug transporters (RT-qPCR) and assessment of cross-resistance (MTT assay).
Main Results:
- CR and FR sublines showed >3-fold resistance to their respective drugs, with reduced proliferation and migration.
- Resistant cells exhibited altered cell cycle and transportome, including downregulated uptake and upregulated efflux transporters (MRP3/4).
- FR cells displayed cross-resistance to irinotecan and gemcitabine; CR cells showed cross-resistance to 5-FU and other platinum derivatives.
Conclusions:
- Novel CCA chemoresistant cell lines (CR and FR) were successfully established.
- These models provide valuable tools for studying CCA chemoresistance mechanisms.
- The findings support the development of new therapeutic strategies to overcome drug refractoriness in CCA.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
